“Rise in prevalence of lifestyle diseases such as depression and chronic pain, increase in number of neurological disorders, and investment for neurological R&D are the factors that drive the growth of the global deep brain stimulation devices.”
The Patient Programmer leverages Samsung Knox security technology to help protect the device and patient. The Patient Programmer consists of two components — a programmer handset and a communicator, designed to help patients get the most from their DBS therapy. The programmer utilizes a Samsung smartphone, with a customized, intuitive user interface, on a large 5-inch color touchscreen. The network-connected smartphone and system design lays the foundation for patient data to be shared directly with clinical staff. Clinicians can also define settings and coordinate directly with their patients to adjust DBS therapy settings between clinic visits.
The communicator is a separate device that synchronizes with the implanted device and provides a secure connection to the programmer handset. When patients want to adjust physician-prescribed therapy settings, turn therapy on or off, or check the neurostimulator’s battery, they simply hold the communicator over the implanted device and make desired changes using the programmer.
To Know COVID-19 IMPACT on Deep Brain Stimulation Devices Industry Download@ https://bit.ly/3fiyvg8
Deep brain stimulation (DBS) is a neuromodulatory approach for treatment of several neurological and psychiatric disorders. A new focus on optimising the waveforms used for stimulation is emerging regarding the mechanism of DBS treatment. Many existing DBS devices offer only a limited set of predefined waveforms, mainly rectangular, and hence are inapt for exploring the emerging paradigm. Advances in clinical DBS are moving towards incorporating new stimulation parameters, yet we remain limited in our capacity to test these in animal models, arguably a critical first step. Accordingly, there is a need for the development of new miniature, low-power devices to enable investigation into the new DBS paradigms in preclinical settings.
North America is the highest revenue contributor in the deep brain stimulation devices market, accounting 40.0% share in 2018 due to increasing prevalence of neurological disorders, growing geriatric population, and recent approvals of deep brain stimulators by Health Canada are expected to drive the market. On the other hand, Asia-Pacific is expected to grow at a CAGR of 19.2%, owing to increased awareness regarding mental health and increase in incidence of neurological disorders drive the market growth.